Vor Biopharma (VOR) director awarded 57,162 stock options at $14.09 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vor Biopharma Inc. director Michel Detheux received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. These are compensation-related awards, not open-market purchases.
One thirty-sixth of the option grant will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, conditioned on Detheux’s continued service. Following this award, he holds options for 57,162 shares directly according to this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Detheux Michel
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 57,162 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 57,162 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 57,162 options
Exercise price: $14.09 per share
Expiration date: June 10, 2036
+3 more
6 metrics
Option grant size
57,162 options
Stock option award to director Michel Detheux
Exercise price
$14.09 per share
Exercise price of granted stock options
Expiration date
June 10, 2036
Option expiration for this grant
Underlying shares
57,162 shares
Common stock underlying the option grant
Post-grant holdings
57,162 options
Total options held following this transaction
Initial vesting date
July 11, 2026
First one-thirty-sixth of options vests
Key Terms
Stock option (right to buy), exercise price, expiration date, Common stock, +1 more
5 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 14.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common stock financial
"underlying_security_title: Common stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vesting financial
"shares subject to the option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Vor Biopharma (VOR) director Michel Detheux report on this Form 4?
Michel Detheux reported receiving a grant of stock options for 57,162 Vor Biopharma common shares. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price if they vest.
What is the exercise price and expiration date of Michel Detheux’s Vor Biopharma options?
Detheux’s options have an exercise price of $14.09 per share and expire on June 10, 2036. This means he can choose to buy shares at $14.09 any time after vesting and before the 2036 expiration date.
Is Michel Detheux’s Vor Biopharma Form 4 a stock purchase or a compensation grant?
The Form 4 reflects a compensation grant, not a market purchase. The transaction code “A” and description show it is a grant or award of stock options, giving Detheux the right to acquire shares in the future if vesting conditions are met.
How do Michel Detheux’s Vor Biopharma options vest over time?
One thirty-sixth of the 57,162 options will vest on July 11, 2026, with additional portions vesting monthly. Vesting continues each month as long as Detheux remains in service, gradually increasing the number of exercisable options he can use.